Your browser doesn't support javascript.
APT™ T3X on the COVID-19 Contamination Rate
ClinicalTrials.gov; 18/01/2021; TrialID: NCT04716426
Clinical Trial Register | ICTRP | ID: ictrp-NCT04716426
ABSTRACT

Condition

COVID-19

Intervention

Drug Tetracycline hydrochloride 3%;Drug Placebo

Primary 

outcome:

COVID-19 Contamination Rate.

Criteria


Inclusion Criteria

- good general health (without serious health problems);

- tested negative, by means of immunoglobulin (Ig) G and IgM serology tests and chain
real-time polymerase chain reaction (RT-PCR), for COVID-19.

Exclusion Criteria

- previous immunization against COVID-19;

- allergy to tetracycline hydrochloride;

- diagnosis of Lyme disease;

- immunocompromised;

- share housing with someone diagnosed with COVID-19 at the time of the baseline
evaluation;

- serious illnesses, such as cancer, kidney failure, decompensated cardiorespiratory and
metabolic diseases, etc.


Collection: Clinical trial registers Database: ICTRP Year: 2021 Document Type: Clinical Trial Register

Similar

MEDLINE

...
LILACS

LIS

Collection: Clinical trial registers Database: ICTRP Year: 2021 Document Type: Clinical Trial Register